A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Public ClinicalTrials.gov record NCT02576431. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion
Study identification
- NCT ID
- NCT02576431
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 215 participants
Conditions and interventions
Conditions
Interventions
- BAY2757556 (Larotrectinib, Vitrakvi) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2015
- Primary completion
- Sep 28, 2025
- Completion
- Sep 28, 2025
- Last update posted
- Apr 27, 2026
2015 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford Cancer Center Palo Alto | Palo Alto | California | 94304 | — |
| UCLA Health Santa Monica Cancer Care | Santa Monica | California | 90404 | — |
| Memorial Cancer Institute at West | Pembroke Pines | Florida | 33026 | — |
| The University of Chicago Medical Center - Hyde Park - Hematology & Oncology | Chicago | Illinois | 60637 | — |
| Mass General Cancer Center | Boston | Massachusetts | 02114-2696 | — |
| Dana-Farber Cancer Institute - Oncology Department | Boston | Massachusetts | 02215 | — |
| Memorial Sloan Kettering Cancer Center New York - Main Campus | New York | New York | 10065 | — |
| UNC Hospitals - UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27514 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| Cleveland Clinic - Neurology | Cleveland | Ohio | 44195 | — |
| Sidney Kimmel Cancer Center - Jefferson Health | Philadelphia | Pennsylvania | 19107 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Avera Cancer Institute - Sioux Falls | Sioux Falls | South Dakota | 57105 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| The University of Texas MD Anderson Cancer Center - Texas Medical Center | Houston | Texas | 77030 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Fred Hutch Cancer Center - Sloan Clinic 1 | Seattle | Washington | 98109 | — |
| West Virginia University | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02576431, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02576431 live on ClinicalTrials.gov.